The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte has announced it has secured a contract with the Strategic Acquisition Center of the U.S. Department of Veterans Affairs to provide its Symvess acellular tissue engineered vessel.
This “Surgical Implant- Next Generation” contract is expected to broaden access to Symvess for veterans across the U.S., signaling a notable achievement for the company's distribution strategy. The agreement underlines growing demand for innovative vascular solutions in national health systems. Details on contract terms and rollout are pending.
Humacyte has previously presented findings on the performance of its acellular tissue engineered vessels for dialysis access at the VASA conference. The research focused on clinical outcomes for patients requiring vascular access. This followed efforts to demonstrate Symvess’s utility in various medical settings.